Liver Cancer Market Size, Share, Trends, Growth 2032

Liver Cancer Industry Prospective:

The global liver cancer market size was worth around USD 6.41 billion in 2023 and is predicted to grow to around USD 14.64 billion by 2032 with a compound annual growth rate (CAGR) of roughly 9.60% between 2024 and 2032.

Request Free Sample

Liver Cancer Market: Overview

Liver cancer is caused by uncontrollable growth of liver cells resulting in the formation of malignant tumors. The most common symptoms of liver cancer include weight loss, abdominal pain or discomfort, vomiting, nausea, jaundice, fever, and itching. Additionally, liver cancer originating in the blood cells is known as angiosarcoma and it is an extremely rare form of the disease.

According to market research, certain cases of liver cancer can be tracked to specific causes such as the prevalence of chronic hepatitis infections. However, in a large portion of liver cancer cases, the cause cannot be determined with accuracy and it may appear in people with no underlying reasons.

Certain risk factors are associated with liver cancer including certain liver diseases inherited from generations, cirrhosis, chronic infection with hepatitis C virus (HCV) or hepatitis B virus (HBV), diabetes, exposure to aflatoxins, nonalcoholic fatty liver disease, excessive alcohol consumption. The growing investments in liver cancer research and innovation are expected to fuel the market demand rate in the coming years.

In addition to this, growing awareness about the condition and early diagnosis may create extensive growth opportunities. The industry is expected to be impacted by the high cost of lung cancer treatment and the inefficiency of the treatment plans to treat the condition, especially in advanced stages.

Key Insights:

• As per the analysis shared by our research analyst, the global liver cancer market is estimated to grow annually at a CAGR of around 9.60% over the forecast period (2024-2032)
• In terms of revenue, the global liver cancer market size was valued at around USD 6.41 billion in 2023 and is projected to reach USD 14.64 billion by 2032.
• The market is projected to grow at a significant rate due to the rising number of liver cancer patients worldwide.
• Based on the treatment, the surgery segment is growing at a high rate and will continue to dominate the global market as per industry projections.
• Based on the disease type, the hepatocellular carcinoma segment is anticipated to command the largest market share.
• Based on region, North America is projected to dominate the global market during the forecast period.

Liver Cancer Market: Growth Drivers

Rising number of liver cancer patients worldwide will drive the market demand rate

The global liver cancer market is expected to be driven by the rising number of patients with the condition. According to the American Cancer Society, more than 800,000 people worldwide are diagnosed with the condition per year. It is also one of the leading causes of cancer-related deaths globally, taking the lives of more than 700,000 people annually. Liver cancer can be induced by several known and unknown factors.

For instance, excessive consumption of alcohol is a known and leading cause of the disease. According to the Centers for Disease Control and Prevention (CDC), all forms of liquor including white or red wine, beer, and other beverages increase the risk of cancer. In addition to this, certain liver cancer cases are genetically inherited. For instance, Wilson’s disease of hemochromatosis can emerge as a cause of cancer.

On the other hand, chronic infection related to HBV and HCV can also induce the disease. The latter is a blood-borne condition leading to liver inflammation. It can be life-threatening in certain cases. The changing consumer lifestyle, exposure to toxic content, diminishing environmental quality, and sedentary lifestyle are expected to contribute to the growing population of patients with liver cancer.

Increased inclusion of the general population in healthcare systems to create more revenue in the industry

Governments and welfare bodies across the globe are working toward improving the global healthcare infrastructure. The introduction of extensively inclusive healthcare plans along with rising access to medical insurance covering major conditions has been beneficial to the global liver cancer market. These initiatives are expected to help liver cancer treatments reach the masses including people in low or middle-income groups.

In June 2024, The Guardian Life Insurance Company of America announced a partnership with Osara Health. The venture will facilitate access to Sara Health’s Cancer Coach program, a cancer support service using the integrated disability claim management processes by Guardian.

Liver Cancer Market: Restraints

High cost of treatment impacts the overall revenue of the industry.

The global industry for liver cancer is expected to be restricted due to the high cost of the treatment. The cost increases further if the requirement for a liver transplant is raised during the treatment. The total expense of liver cancer depends on the type of treatment, stage of the condition, and overall economic strength of the region.

For instance, a liver transplant in the US can cost over USD 800,000. Furthermore, additional expenses associated with postoperative treatment and rehabilitation can further discourage higher revenue in the industry.

Liver Cancer Market: Opportunities

Liver cancer research and innovation to generate growth opportunities in the future

The global liver cancer market is expected to generate growth opportunities due to the growing research and innovation in disease diagnosis, treatment, and management. In 2020, scientists at the National Cancer Institute announced the development of a novel blood test among a small group segment.

The results of the blood test positively indicated people with chronic liver disease who later developed HCC. According to the official reports, the test was beneficial in diagnosing people with HCC almost a decade before their cancer was diagnosed.

In March 2023, researchers from the Massachusetts General Hospital and National Institutes of Health announced that they had discovered a potential novel approach against liver cancer. The research could lead to the development of a new class of anticancer medication.

According to the research conducted on mice and in cells, the studies indicated that an enzyme produced by liver cancer cells could be used for converting a specific group of compounds in anticancer drugs. Thus, killing the cancer cells and reducing the disease in animals. In a recent event, the European Union launched the THRIVE project. The region aims to improve the prognosis of liver cancer among adults and children.

Liver Cancer Market: Challenges

Side-effects of treatment and regulatory complexities to challenge market expansion trends

The global industry for liver cancer is expected to be challenged by the severe side effects associated with some of the liver cancer treatments. For instance, constant fatigue, loss of hair, and development of skin disorders are some of the most commonly observed side effects of liver treatment. Furthermore, regulatory complexities associated with medicines and liver cancer-treatment procedures may also inhibit the industry’s growth rate.

Liver Cancer Market: Report Scope

Liver Cancer Market: Segmentation

The global liver cancer market is segmented based on treatment, stage of the cancer, disease type, and region.

Based on the treatment, the global market segments are targeted therapy, radiation therapy, surgery, chemotherapy, and immunotherapy. In 2023, the highest growth was listed in the surgery segment. The treatment method deals with the removal of the tumor in the liver causing the cancer. According to market analysis, patients who have undergone surgery for the removal of HCC have shown improvements of 35% to 50% in 5-year survival rate in recent times.

Based on the stage of the cancer, the global liver cancer industry is divided into advanced stage, intermediate stage, and early stage.

Based on the disease type, the global market divisions are hepatoblastoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and fibrolamellar carcinoma. According to Mayo Clinic, the most common type of live cancer is hepatocellular carcinoma (HCC). It starts in the main cell type of the organ called the hepatocytes. The National Institute of Health (NIH) predicts that around 0.5 million cases of HCC are reported worldwide every year.

Liver Cancer Market: Regional Analysis

North America to dominate the highest market share during the projection period

The global liver cancer market is expected to be led by North America during the projection period. In 2023, it held control over 35.01% of the overall market revenue with the US leading from the front. The regional market dominance is a result of a robust cancer treatment, diagnosis, and research environment focusing on making new strides in treating patients with the disease.

In October 2024, researchers at the VCU Massey Comprehensive Cancer Center, a major cancer research and treatment institution, received an award for USD 13 million from the National Cancer Institute through a team science grant. The multi-disciplinary group of scientists will work on improving treatment for HCC, the most common type of liver cancer.

In November 2023, Karmanos Cancer Institute, one of the largest cancer care providers in the Michigan area of the US, announced that it received the country’s first approval from the Food & Drugs Administration (FDA) authority for using TheraBionic P1 device for treating advanced stages of hepatocellular carcinoma. In addition to this, growing awareness around liver cancer along with the presence of a comprehensive medical reimbursement infrastructure further helps the region thrive.

Liver Cancer Market: Competitive Analysis

The global liver cancer market is led by players like:

• Novartis AG
• Bristol-Myers Squibb
• Celsion Corporation
• Johnson & Johnson
• Merck & Co.
• Eli Lilly and Company
• Bayer AG
• Amgen Inc.
• Roche
• Sanofi
• Pfizer Inc.
• AbbVie Inc.
• Eisai Co. Ltd.
• AstraZeneca
• Exelixis Inc.

The global liver cancer market is segmented as follows:

By Treatment

• Targeted Therapy
• Radiation Therapy
• Surgery
• Chemotherapy
• Immunotherapy

By Stage of the Cancer

• Advanced Stage
• Intermediate Stage
• Early Stage

By Disease Type

• Hepatoblastoma
• Intrahepatic Cholangiocarcinoma
• Hepatocellular Carcinoma
• Fibrolamellar Carcinoma

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa